The p53 Y220C mutation swaps a bulky tyrosine residue for a smaller cysteine at position 220 in the DNA-binding domain of the p53 tumor suppressor protein, carving out a surface cavity that destabilizes the protein by roughly 4 kcal/mol and causes most of it to unfold at body temperature. That unfolding strips p53 of its ability to bind DNA, activate its target genes, and suppress tumor growth. The mutation is estimated to appear in about 75,000 new cancer cases each year, and because the cavity it creates is druggable, Y220C has become one of the most intensely studied targets for pharmacological rescue of mutant p53.
What Y220C Does to the Protein’s Architecture
Wild-type p53’s DNA-binding domain is built around a central sandwich of beta sheets that supports the DNA-contacting surface: a loop-sheet-helix motif and two large loops (L2 and L3) held together by a zinc ion coordinated by three cysteines and a histidine.1Protein Engineering, Design and Selection. Stabilising the DNA-binding domain of p53 by rational design of its hydrophobic core Even in its normal state, this domain is remarkably fragile. It melts just above body temperature and has a free energy of stabilization of only about 6 kcal/mol at 25°C.2PubMed. Thermodynamic stability of wild-type and mutant p53 core domain NMR studies have shown the domain is far more mobile in solution than crystal structures suggested, with buried polar groups forming suboptimal hydrogen-bond networks that partly explain why it is so easy to destabilize.3PubMed Central. Solution structure of p53 core domain: structural basis for its instability
Position 220 sits at the junction of two proline-rich loops, called S3/S4 and S7/S8, away from the DNA-binding surface itself. In the wild-type protein, the tyrosine at this spot participates in several electrostatic interactions with neighboring residues on those loops, helping to hold the local scaffold together.4PubMed. Effect of Y220C mutation on p53 and its rescue mechanism: a computer chemistry approach When the large tyrosine side chain is replaced by the much smaller cysteine, those stabilizing contacts are lost, and the space the tyrosine once filled becomes an empty surface crevice. This is not a subtle rearrangement. The mutation effectively merges two pre-existing smaller cavities into one extended groove on the protein surface.5PubMed Central. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm The crevice is narrow, flanked by those two proline-rich loops, and reaches its greatest depth right at the mutation site.6Structure. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53
How Destabilization Leads to Loss of Function
The cavity costs the protein about 4 kcal/mol of thermodynamic stability, which for an already marginally stable protein is devastating.7PubMed Central. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug The melting temperature of the Y220C mutant drops to around 40.3°C, only a few degrees above normal body temperature, meaning a large fraction of the protein population is unfolded under physiological conditions. Thermal stability measurements indicate that over 80% of the Y220C mutant protein is unfolded and transcriptionally inactive in the cell.8PubMed Central. Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry
This matters because p53 can only do its job as a transcription factor when it is properly folded and able to latch onto specific DNA sequences in the promoter regions of its target genes. Once unfolded, the protein loses its DNA-binding capacity and can no longer switch on the genes responsible for cell-cycle arrest, DNA repair, and programmed cell death. The Y220C mutation therefore falls into the category of structural mutations: it does not directly damage the DNA-contact surface the way some other p53 mutations do, but it collapses the overall fold so thoroughly that the contact surface never gets a chance to work.
There is an additional wrinkle. Unfolded or partially folded p53 is prone to forming amyloid-like aggregates, sticky clumps of misfolded protein that can sequester any remaining functional p53 and even interfere with related family members. Research on hepatocellular carcinoma cell lines has shown that Y220C mutant p53 readily forms these aggregates, which may further promote tumor progression beyond simple loss of transcriptional activity.9PubMed Central. PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma
Effects on Cell Growth, Migration, and Cancer Behavior
When researchers introduce the Y220C mutant into p53-null cancer cells in the laboratory, the results go beyond a simple loss of tumor suppression. Experiments in non-small cell lung cancer cells showed that overexpressing Y220C mutant p53 enhanced cell proliferation, wound healing, and invasive capacity compared to both control cells and cells expressing wild-type p53.10PubMed Central. Triptolide promotes degradation of the unfolded gain-of-function Tp53 R175H/Y220C mutant protein by initiating heat shock protein 70 transcription in non-small cell lung cancer In transwell migration and invasion assays, cells carrying Y220C moved through barriers significantly more aggressively than their wild-type counterparts. This points to Y220C having gain-of-function properties: it does not simply lose the ability to stop tumors; it actively helps them grow and spread.
At the gene-expression level, the consequences are equally stark. The mutation results in decreased DNA binding, reduced transcriptional activity, resistance to apoptosis, and failure of normal G1 cell-cycle arrest in cultured cells. The genes that wild-type p53 would normally switch on to halt the cell cycle (like CDKN1A, which encodes the p21 protein) or trigger programmed cell death (like BBC3/PUMA and NOXA) remain silent. Without these brakes, the cell divides when it should stop, survives when it should die, and accumulates further genetic damage unchecked.
Where Y220C Shows Up in Cancer
Y220C is not evenly distributed across cancer types. A landscape analysis of 498 patients with Y220C-mutated solid tumors found the most common tumor types to be ovarian cancer (22%), pancreatic cancer (11%), breast cancer (11%), and non-small cell lung cancer (10%). The mutation was especially concentrated in high-grade serous ovarian cancer, where its prevalence reached about 4.5%.11Cancer Research. The landscape of TP53 Y220C mutations in cancer In colorectal carcinoma, Y220C appears in roughly 0.6% of cases, a smaller fraction but still numbering in the thousands annually given how common colorectal cancer is.12Journal of Clinical Oncology. TP53 Y220C mutations in colorectal carcinoma (CRC): A genomic landscape study
The concentration in ovarian cancer is worth noting because high-grade serous ovarian cancer already has one of the highest rates of TP53 mutations of any cancer type, with almost all cases carrying some form of p53 alteration. Y220C’s 4.5% share may sound modest, but in a malignancy where p53 dysfunction is nearly universal, being the predominant single missense variant gives it outsized clinical relevance as a drug target.
Why Y220C Is Considered Druggable
Most p53 mutations are notoriously difficult to target with drugs because they either destroy a flat DNA-contact surface (leaving no pocket for a small molecule to grip) or cause such catastrophic unfolding that there is little stable structure left to stabilize. Y220C is different. The mutation creates a well-defined, narrow crevice on the protein surface, away from the functional DNA-binding region. Researchers have subdivided this crevice into a central cavity and three subsites, providing multiple docking points for small molecules.6Structure. Exploiting Transient Protein States for the Design of Small-Molecule Stabilizers of Mutant p53 Because the cavity is the direct cause of destabilization and sits at a non-functional site, a molecule that fills it can thermodynamically stabilize the protein without interfering with DNA binding. In principle, you are replacing what tyrosine used to do with a chemical prosthetic.
This concept has been validated progressively over more than a decade. Early carbazole-based compounds like PK083 bound the cavity and improved thermal stability, and structural optimization by targeting an unoccupied subsite of the crevice achieved roughly a 70-fold increase in binding affinity, pushing it down to single-digit micromolar levels. One such compound, PK9318, restored p53 signaling in a liver cancer cell line carrying a homozygous Y220C mutation.13PubMed Central. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C Another compound, PK7088, increased the amount of properly folded mutant protein with wild-type conformation, restored transcriptional function, and induced Y220C-dependent growth inhibition, cell-cycle arrest, and apoptosis. It boosted expression of p21 and the pro-apoptotic NOXA protein.14PubMed Central. Small molecule induced reactivation of mutant p53 in cancer cells
Covalent Rescue and the Move Toward the Clinic
A critical advance came with the development of compounds that form a covalent bond with the mutant cysteine at position 220. Because only the mutant protein has a cysteine at that site, covalent binders are inherently selective for Y220C over wild-type p53. One such series of azaindole-based compounds was shown to selectively react with the Y220C cysteine and restore wild-type thermal stability to the mutant protein.15PubMed Central. A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability In cell-based assays, one of these molecules, KG13, upregulated the p53 target gene CDKN1A by about 7-fold in one cell line and over 10-fold in another, prolonged p53 Y220C occupancy on gene promoters, and induced caspase activity selectively in Y220C-carrying cells but not in wild-type p53 cells.16Cancer Discovery. A Small Molecule Reacts with the p53 Somatic Mutant Y220C to Rescue Wild-type Thermal Stability
The most clinically advanced molecule in this space is rezatapopt (also known as PC14586). Rezatapopt was designed specifically to reactivate Y220C mutant p53 by correcting its conformation and enabling it to bind DNA and switch on downstream target genes, thereby inducing anti-proliferative changes in tumor cells. Preclinical work showed potent anti-tumor activity as a single agent and in combination with immunotherapy.17Cancer Discovery. Restoration of the Tumor Suppressor Function of Y220C-Mutant p53 by Rezatapopt, a Small-Molecule Reactivator Rezatapopt is currently being evaluated in a registrational phase II clinical trial for patients with advanced solid tumors carrying the Y220C mutation, making it the first Y220C-specific compound to reach this stage of clinical development.
Combination Strategies and Future Directions
Even a potent reactivator of Y220C may benefit from combination with other treatments, since tumors typically rely on multiple survival pathways. Systematic evaluation of rezatapopt alongside standard-of-care agents, including chemotherapy and bevacizumab, showed in vivo efficacy for those combinations. But a high-throughput drug screen turned up something more interesting: the PI3K/AKT/mTOR and MAPK signaling pathways emerged as top synergistic candidates. Validation experiments confirmed that inhibiting the PI3Kα enzyme alongside rezatapopt deepened apoptosis and improved tumor growth inhibition in animal models beyond what either agent achieved alone.18PubMed Central. Systematic Evaluation of Combination Strategies with Rezatapopt in p53 Y220C-Mutant Cancer Models
A separate approach targets Y220C not by stabilizing the mutant protein but by recruiting the histone acetyltransferase p300/CBP to acetylate it, which upregulates apoptotic genes and downregulates DNA damage response pathways. These bifunctional molecules represent a different philosophy: rather than trying to restore wild-type folding, they accept the mutation and chemically redirect the protein toward tumor-suppressive gene programs anyway. Both approaches, conformational rescue and functional redirection, are being pursued in parallel, reflecting how seriously the field takes Y220C as a tractable cancer target.
Beyond Y220C Alone
The Y220C story has implications for the broader universe of p53 mutations. About a third of all cancer-associated p53 mutations work by lowering the protein’s melting temperature rather than directly hitting the DNA-binding residues.7PubMed Central. Targeted rescue of a destabilized mutant of p53 by an in silico screened drug Y220C is the poster child for this class because it creates such a clean, well-defined druggable pocket, but the principle of stabilizing a destabilized mutant with a small molecule could theoretically extend to other cavity-creating mutations. Other substitutions at position 220, such as Y220S (tyrosine to serine), create a similar cavity, suggesting the therapeutic strategy might generalize at least within the Y220X family.5PubMed Central. Targeting Cavity-Creating p53 Cancer Mutations with Small-Molecule Stabilizers: the Y220X Paradigm
Computational methods have played a large role in accelerating this work. Molecular dynamics simulations and docking studies have been used to understand the structural dynamics of the Y220C mutant, identify putative rescue pockets, and screen virtual fragment libraries for potential stabilizing ligands.19Protein Engineering, Design and Selection. An in silico algorithm for identifying stabilizing pockets in proteins: test case, the Y220C mutant of the p53 tumor suppressor protein These computational approaches are not just helpful for Y220C; they serve as a proof-of-concept pipeline for tackling other destabilizing p53 mutations that might harbor their own cryptic pockets. Whether any of those pockets turn out to be as accessible and druggable as the Y220C crevice remains to be seen, but the molecular toolbox is now considerably more developed than it was a decade ago.
The Aggregation Problem
One aspect of Y220C biology that complicates both the science and the therapy is protein aggregation. As noted earlier, the destabilized mutant protein tends to form amyloid-like aggregates. These aggregates are not just inert lumps of misfolded protein; they can have a dominant-negative effect by trapping wild-type p53 (in cells that still have one normal copy) into co-aggregates, effectively silencing the last functional copy of the gene. In hepatocellular carcinoma cell lines, the drug PRIMA-1 was shown to inhibit Y220C mutant p53 aggregation and synergize with cisplatin in killing tumor cells.9PubMed Central. PRIMA-1 inhibits Y220C p53 amyloid aggregation and synergizes with cisplatin in hepatocellular carcinoma This dual role, both aggregation inhibitor and chemotherapy sensitizer, suggests that managing the misfolded protein’s tendency to clump may be just as important as restoring its fold.
The interplay between unfolding and aggregation creates a race condition in the cell. A stabilizing drug needs to catch the mutant protein while it is still in a near-native, foldable state, before it has tumbled into an irreversible aggregate. This is why the thermal stabilization achieved by cavity-binding molecules matters so much practically: pushing the melting temperature up by even a few degrees can dramatically shift the balance from aggregated-and-lost toward folded-and-functional. The early carbazole binders slowed aggregation rates measurably, and compounds with tighter binding showed proportionally better protection, consistent with the idea that filling the cavity acts as a physical plug that keeps the protein’s core from unraveling long enough for it to do its job.13PubMed Central. A structure-guided molecular chaperone approach for restoring the transcriptional activity of the p53 cancer mutant Y220C
Allosteric Ripple Effects of the Mutation
The Y220C mutation’s effects are not entirely local. Molecular dynamics studies have found that the cavity alters the dynamic behavior of residues far from position 220, including residues in the DNA-binding loops themselves. One study tracked how allosteric effector molecules influenced the binding behavior of lysine 120, a residue critical for DNA contact, and found that Y220C dramatically dampened its binding events compared to the wild-type protein.20PubMed Central. Reconnaissance of Allostery via the Restoration of Native p53 DNA-Binding Domain Dynamics in Y220C Mutant p53 Tumor Suppressor Protein This means Y220C is not simply a thermodynamic hole in the protein; it also rewires the dynamic communication network within the domain, quieting movements at the DNA-binding interface that the protein needs for function.
This allosteric dimension adds nuance to what a rescue drug needs to accomplish. Filling the cavity and restoring bulk thermal stability may be necessary but not sufficient. An ideal therapeutic would also restore the native dynamic motions at distant sites, essentially re-tuning the protein’s internal communication. Some of the more advanced compounds appear to do this, as judged by the restoration of wild-type transcriptional programs in cell-based assays, but the degree to which allosteric correction versus simple stabilization drives the functional rescue remains an active area of investigation.